Day One Biopharmaceuticals (DAWN)

Executive Summary

Day One Biopharmaceuticals is a clinical-stage oncology company that achieved its first FDA approval in 2024 with OJEMDA (tovorafenib) for pediatric low-grade glioma (LGG). The company's 'Search & Development' model leverages genetic insights to accelerate targeted therapies, with a focus on underserved pediatric and adult patient populations. OJEMDA, a novel RAF inhibitor, is now commercially available, and Day One is actively expanding its clinical pipeline beyond LGG. The company's pipeline includes tovorafenib in Phase 2 for craniopharyngioma and a Phase 3 combination study in LGG, as well as DAY301, a PTK7-targeting antibody-drug conjugate in Phase 1 for advanced solid tumors. With a strong cash position and approved product generating revenue, Day One is well-positioned to deliver near-term catalysts from both clinical data readouts and commercial execution. The company's focus on rare pediatric cancers and biomarker-driven adult indications provides a differentiated risk profile and long-term growth potential.

Upcoming Catalysts (preview)

• H2 2026Phase 2 data for tovorafenib in craniopharyngioma60% success
• H2 2027Initial Phase 1 data for DAY301 in solid tumors40% success
• H1 2027Phase 3 FIREFLY-2 tovorafenib combination study update in LGG70% success